Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses by Nisha R. Patel et al.
ORIGINAL RESEARCH
Stereotactic body radiotherapy for re-irradiation of lung cancer
recurrence with lower biological effective doses
Nisha R. Patel & Rachelle Lanciano & Karna Sura &
Jun Yang & John Lamond & Jing Feng & Michael Good &
Ed J. Gracely & Lydia Komarnicky & Luther Brady
Received: 29 May 2014 /Accepted: 13 November 2014 /Published online: 10 December 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Objective Few studies have evaluated re-irradiation of lung
cancer recurrences with stereotactic body radiotherapy
(SBRT). This study evaluates outcomes with SBRT re-
irradiation for recurrent lung cancer.
Methods Two hundred and seventy-eight patients treated with
SBRT for lung cancer were retrospectively reviewed. Of
those, 26 patients with 29 tumors were re-irradiated with
SBRT. Ninety percent of tumors received prior external beam
irradiation and 10 % received prior SBRT. Previous median
radiation dose was 61.2 Gy with a median 8-month interval
from previous radiation. The median re-irradiation SBRT dose
was 30 Gy (48 Gy10 biological effective dose (BED)). End-
points evaluated included local control, overall survival, and
progression-free survival.
Results Twenty-five of 29 tumors were evaluable for local
control, with 27 tumors (93 %) considered in-field recur-
rences. In-field crude local control rate was 80 % (20/25) with
1 and 2-year actuarial rates of 78.6 and 65.5 %, respectively.
One and 2-year actuarial survival rates were 52.3 and 37.0 %,
respectively. One and 2-year actuarial progression-free surviv-
al rates were 56.7 and 37.0 %, respectively. Fifty-five percent
of patients reported acute/chronic grades 1 and 2 toxicities. No
grade 3 or higher toxicities were reported.
Conclusion Patients with recurrent lung cancer have limited
options. SBRT re-irradiation is tolerable even after a median
61.2 Gy to the re-irradiation site. The lower BED used
provided acceptable progression-free survival with low toxic-
ity. Given the poor prognosis with current treatment options,
new paradigms for re-treatment should include SBRT-re-
irradiation as an adjunct to systemic therapy for in-field lung
cancer recurrence.
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Introduction
Treatment for locally advanced lung cancer has improved
since the 1990s from external beam radiation (EBRT) alone
to concurrent chemotherapy and radiation providing survival
benefit [1–5]. Nearly 70 % of patients diagnosed with lung
cancer will receive EBRT as initial treatment [6]. Despite the
use of concurrent chemotherapy with EBRT, local-regional
relapse can occur in up to 50 % of patients [1]. Treatment
options for lung recurrence remain limited. Fibrosis and de-
creased functional lung reserve after previous thoracic irradi-
ation in the face of baseline pulmonary disease can limit
surgical options. The use of external beam re-irradiation has
demonstrated significant toxicity and limited overall survival
[7–12]. Second-line salvage chemotherapy remains a standard
alternative therapy. However, low response rates and short
durable control reinforce the need for improved local treat-
ment modalities [13].
Few series have reported treatment outcomes for stereotac-
tic re-irradiation for lung cancer recurrence after previous
EBRT/SBRT with local control rates from 52 to 92 % and
low progression-free survival [14–18]. Nearly 50 % of pa-
tients experienced worsening dyspnea with 33 % grade 3 or
higher toxicity after SBRT re-irradiation, with median biolog-
ical effective dose (BED) of 100 Gy10 in one of the largest
series to date [14]. Although delivery of BEDs of at least
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100 Gy10 has demonstrated excellent local control rates and
improved survival for treatment of early stage medically in-
operable lung cancer, these doses in the re-irradiation setting
may not be appropriate given the higher risk of associated
toxicity [19–22]. This study reports a single institutional ex-
perience for re-irradiation with SBRT for in-field lung cancer
recurrence and evaluates any apparent differences in outcome
with the use of lower BEDs than used for primary treatment.
Methods
The records of 278 consecutive patients treated with SBRT for
lung cancer at Philadelphia CyberKnife, from January 2008 to
December 2011, were retrospectively reviewed. Of those 278
patients, 26 patients with 29 tumors that received SBRT re-
irradiation were further analyzed on this IRB-approved retro-
spective study. Twenty-six tumors previously received stan-
dard fractionated EBRT, and three tumors received SBRT
prior to SBRT re-irradiation for lung recurrence. A minimum
of 3-month follow-up with CT or PET/CT was required for
evaluation of local control with 25 out of 29 tumors evaluable
for local control. All patients were evaluable for survival.
Local failure was defined as relapse within the SBRT PTV.
Response evaluation criteria in solid tumors was used as a
general guideline, and the use of PET/CT with SUV greater
than or equal to pre-treatment values was considered a recur-
rence as previously reported [23]. Other patterns of failure
including out-of-field thoracic progression and distant metas-
tases were also evaluated by CT or PET/CT for progression-
free survival analysis.
All patients were treated supine with the CyberKnife ste-
reotactic system. Treatment planning included inspiration and
expiration CTof chest to evaluate movement of the GTV with
respiration. KV orthogonal imaging was used for real-time
target tracking with either fiducial (n=9), x-site lung (n=3),
or x-site spine (n=17). Internal target volume was delineated
for patients tracked with x-site spine. All clinical target vol-
umes had an isotropic 5-mm expansion to create the planning
target volume to account for inherent set up error/imaging lag
time. Non-coplanar pencil beams using 6MV photons with
ray-tracing dosimetric calculation for delivered dose were
utilized for all treatment plans except one. Monte Carlo cal-
culations were used for a single treatment plan; this option has
since become the standard method of dose calculation within
our institution. All treatment plans were evaluated to deter-
mine whether the re-treated SBRT lesion was considered an
“in-field recurrence” of the previous radiation course as re-
ported in other series [14] (Fig. 1). There were two tumors
juxtaposed at the 50 % isodose line or field edge of previous
external beam radiation plan that were considered marginal
relapses with all other re-treated tumors considered to be in-
field relapses. The Kaplan-Meier method was used to
calculate the actuarial local control and overall survival rate.
Statistical significance was evaluated by the log-rank test.
Potential differences for local control between BED <48 and
BED ≥48 Gy10 were also evaluated using the χ2 test.
Results
Patient characteristics are illustrated in Table 1. The median
age was 68 years old (range 42–87). Of the 26 patients, 19
(73 %) were women and 7 (27 %) were men. The patients’
initial presentation at diagnosis was predominantly locally
advanced non-small cell lung cancer (NSCLC) with 15
(58 %) patients stage III disease and 23 (88 %) non-small cell
histology. The majority, 19 patients (73 %), previously re-
ceived definitive external beam radiation therapy. Two pa-
tients (8 %) previously had postoperative radiation, two pa-
tients (8 %) previously received palliative radiation, and three
patients (11 %) had prior SBRT. Initial chemotherapy was
Fig. 1 Composite plan of a patient who initially received 54 Gy external
beam radiation for a left upper lobe adenocarcinoma. She was re-
irradiated with SBRT 25 Gy in 5 fractions for an in-field recurrence in
left upper lobe and subsequent 50 Gy in 5 fractions for a marginal right
hilar recurrence. Note fiducials in each site of re-irradiation SBRT. Patient
survived 45 months after initial SBRT re-irradiation
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administered to 24 patients: concurrently with radiation in 21
(81 %) and adjuvantly in three patients (11 %).
The median interval time from previous EBRT or SBRT to
re-irradiation with SBRT was 8 months (range 3–26 months)
(Table 2). Twenty-six tumors (90 %) had previous EBRT, and
three tumors (10 %) had previous SBRT. A total of 27 tumors
(93 %) were considered in-field recurrences receiving at least
30 Gy from previous radiation treatment with two marginal
relapses. There were 17 peripheral tumors and 12 central
tumors. The median previous dose of EBRT was 61.2 Gy
(30–74 Gy) with three patients that had original diagnosis of
stage IV disease accounting for previous lower palliative
doses. Stable distant or intrathoracic metastatic disease was
present in four patients at the time of re-irradiation with SBRT.
After re-irradiation, 50 % (13 patients) received
chemotherapy.
Median prescribed dose of SBRT for re-irradiation was
30 Gy (15–50, median BED of 48Gy10) delivered for a
median of 5 fractions (range 3–5) prescribed to a median
69 % isodose line (range 55–85 %). The median tumor size
treated was 3.2 cm (1.2–9.5 cm). Since the dose-per-fraction
used in this study is <10Gy, and the LQ model is relatively
accurate in this dose region (<10Gy/day), we adopted the LQ
model to evaluate biological effective dose. Twelve tumors
were treated with BED <48 Gy10 with a median BED dose of
36.6 Gy10 (9.5–42 Gy), and 17 tumors were treated with BED
≥48 Gy10 with a median BED dose of 72.2 Gy10 (48–
112.5 Gy). The EQD2 doses for the two groups were 30.5
and 60 Gy, respectively. Twenty-five tumors were evaluable
with radiographic assessment for 1 and 2-year actuarial local
control rates. All 26 patients were evaluable for 1 and 2-year
actuarial survival and progression-free survival rates. The me-
dian survival from SBRT re-irradiation was 14 months. The 1
and 2-year actuarial survival rates were 52.3 and 37.0 %, re-
spectively, for the study sample. The 1 and 2-year actuarial
progression-free survival rates were 56.7 % (95 % CI 37.3–
76.1) and 37.0 % (95 % CI 16.8–57.2), respectively (Fig. 2),
with no significant difference between BED <48 and BED
≥48 Gy10 (p=0.76). The crude local control was 80 % (20/25)
for the study sample. The 1 and 2-year actuarial local control
rates were 78.6 % (95 % CI 60.0–97.2) and 65.5 % (95 % CI
37.5–93.5), respectively. All five local failures occurred within
the PTV with three failures receiving BED <48 Gy10 and two
failures receiving BED ≥48 Gy10. Further analysis demonstrat-
ed higher 1 year actuarial local control rates for BED ≥48 Gy10
of 90.9 % versus 62.5 % for BED <48Gy10; however, this
difference was not statistically significant (p=0.32). The dura-
bility of local control diminished over time with 2-year actuarial
local control rate of 68.2 % for BED ≥48 Gy10 with a similar
rate of 62.5 % for lower BED <48 Gy10. Further subset analysis
did not demonstrate any statistically significant difference for
local control stratified by peripheral or central location or time
to re-irradiation with less than or greater than 12 months from
initial radiation therapy.
No patients experienced grades 3–5 toxicity based upon the
NCI CTCAE criteria without local thoracic or in-field pro-
gression of disease. One patient was hospitalized for progres-
sive dyspnea with a large malignant pleural effusion and
another patient underwent surgery for tracheoesophageal fis-
tula with the presence of tumor cells noted within the fistula.
Of the 29 treated lesions, 55% experienced acute/late grades 1
and 2 symptoms with four reported symptoms within the dose
range of BED <48 Gy10, and 12 reported symptoms for
delivered doses of BED ≥48Gy10. Reported side effects in-
cluded dyspnea, cough, fatigue, esophagitis, and skin rash
(Table 3).
Table 1 Patient characteristics
Number Percent
Sex Female 19 73
Male 7 27
Initial stage I–II 8 31
III 15 58
IV 3 11
Initial histology NSCL 23 88
Non-NSCL 3 12








parameters Median (Range) BED <48 Gy (n=12) BED ≥48 Gy (n=17)
Previous RT dose (Gy) 61.2 (30–74) 68.3 59.4
Time from prior RT (months) 8 (3–26) 7.5 8
Re-irradiation RT dose (Gy) 30 (15–50) 23 40
Re-irradiation no. of fractions 5 (3–5) 5 5
Re-irradiation BED dose (Gy) 48 (19.5–112.5) 36.6 72.2
Re-irradiation EQD2 dose (Gy) 30.5 60
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Discussion
Lung recurrence after definitive therapy poses a clinical man-
agement dilemma specifically for in-field lung cancer recur-
rences with relatively poor prognosis utilizing currently avail-
able treatment options. There have been few retrospective
studies assessing the role of SBRT re-irradiation for lung
recurrence; however, these studies include small numbers of
patients with heterogeneous populations.
One of the largest series by Kelly et al. from M.D. Ander-
son reported 36 patients with a median time between EBRT
and SBRT of 22.0 months. This study included a heteroge-
neous group with 31 % in-field recurrence, 36 % isolated out-
of field recurrence, and 33 % recurrence in the setting of
controlled disseminated disease [14]. The majority of patients
were treated with 50 Gy in 4 fractions. Two-year intrathoracic
relapse rate was 74 % despite excellent local control rates of
92 % [14]. On subset analysis, the patients treated for out-of-
field recurrence had significantly longer progression-free
survival (p=0.04). Thus, a comparison to our series is difficult
since we primarily report a worse prognostic group of in-field
lung cancer recurrences, which constituted 93% of the current
series.
Peulen et al. also investigated the option of SBRT re-
irradiation with a mean EQD2 dose of 109 Gy after prior
SBRT for 32 lung tumors. Approximately 34% of the patients
had primary lung cancer recurrence while the majority of
patients had re-irradiation for lung metastases from colorectal,
renal cell carcinoma, or other primary sites. The primary
endpoint for this study was toxicity. The patients (n=9)
experiencing grades 3–5 toxicity were found to have larger
CTV volumes during initial SBRT, central tumors, and shorter
median interval time to re-irradiation with SBRT (median
14.5 months) [15]. Of the 10 evaluated centrally treated re-
currences in our study, there were no patients who had expe-
rienced grade 3 or higher toxicity. Although there were three
patients within our study that also underwent re-irradiation
with SBRT following initial SBRT, no patients experienced
grades 4 or 5 toxicities. However, the improved toxicity
profile in our study may be attributed to the lower SBRT re-
irradiation doses in comparison to the above studies.
A small study reporting treatment outcomes specifically for
lung cancer recurrences for SBRT re-irradiation after conven-
tional EBRT was reported by Seung et al., who reported on
eight patients treated with 40–60 Gy in 3 to 5 fractions with
high local control rate of 86 % for lung cancer recurrence after
prior EBRT (median follow-up 18 months). The study was
limited by the small number of patients and did not explicitly
specify whether the lesions were considered in-field or out-of-
field recurrences [16].
Trakul et al. from Stanford also assessed treatment out-
comes for SBRT re-irradiation for in-field recurrences after
prior conventional irradiation [17]. However, this study in-
cluded oligometastatic disease as well as lung cancer recur-
rences. The median BED was 80Gy for re-irradiation with
SBRT that provided local control rates of 65.5% at 12months.
Neither our study nor Trakul et al. reported any grade 2 or
higher pneumonitis, unlike studies using higher re-irradiation
doses [14–16]. Improved local control was also associated
with longer interval time between re-treatment >16 months
(p=0.042).
A recent study by Trovo et al. reported the use of lower
SBRT re-irradiation doses via tomotherapy (30 Gy in 5 to 6
fractions) to in-field recurrences after initial definitive therapy
(n=17) [18]. One-year local control rate was 86 %, and 1 and
2-year rates for overall survival were 59 and 29 %, respec-
tively, with a predominant trend toward distant failure. De-
spite the median interval of 18 months prior to re-irradiation
with SBRT and lower radiation doses, 4 out of 17 patients
(23 %) experienced grade 3 toxicity or higher and two
radiation-related deaths were reported. One patient had per-
sistent hilar disease with fatal hemoptysis, so it is uncertain
Fig. 2 Proportion of patients free from progression over time
Table 3 Grades 1 and 2 toxicity
BED <48 Gy BED ≥48 Gy
Cough Grade 1 0 2
Grade 2 0 1
Pneumonitis Grade 1 0 0
Grade 2 0 1
Esophagitis Grade 1 2 2
Skin Grade 1 1 0
Fatigue Grade 1 0 5
Dyspnea Grade 1 1 1
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whether progression of disease may have been a contributing
factor. In addition, all lesions were centrally located, posing a
significant challenge to minimize potential toxicity to critical
adjacent organs.
The current study evaluated treatment of in-field lung can-
cer recurrence with SBRT re-irradiation after conventional
dose EBRT or SBRT. SBRT re-irradiation was delivered with
a conservative dose of median BED of 48Gy10. There was no
significant difference in 1 to 2-year actuarial local control
between BED <48 Gy10 (EQD2 30.5 Gy) and BED
≥48 Gy10 (EQD2 60 Gy). The small number of patients in this
study may have influenced this result, obscuring a true differ-
ence between the two groups. The 2-year actuarial local con-
trol of 65.5 % for the entire group was in close agreement with
the Trakul et al. study, which reported 1-year actuarial local
control of 65.5 %. Both this study and that of Trakul et al. have
similar patient groups with previous conventional dose EBRT
and re-irradiation with SBRT for in-field recurrence with sim-
ilar local control, progression-free survival, and survival rates.
The Kelly et al. study, which utilized higher dose re-irradiation
with better local control rate, had similar 2-year actuarial
progression-free survival rate to the current series. The poor
2-year actuarial progression-free survival of 37% for our study
and others validates the need to evaluate different paradigms
for treating lung cancer recurrence with combination of
targeted therapies and an appropriate SBRT re-irradiation dose.
The possibility of intrathoracic and distant microscopic disease
at the time of re-irradiation may prevent the benefit from
higher local control rates with 100 Gy10 BED doses.
Potential toxicity also becomes a serious concern when
considering re-irradiation. Without the potential benefit of
progression-free survival, high local control rates may only
add to increased toxicity and poor quality of life depending
upon the location of the lesion. Several studies have suggested
an interval of at least 5–6 months between re-treatment to
mitigate possible toxicity to organs at risk such as the spinal
cord [24, 25]. Despite the shorter median interval time for re-
treatment of 8 months in this study, there were no patients that
experienced grades 3–5 toxicity with the delivery of conser-
vative radiation dose. In total, 55 % of patients had low-grade
toxicity associated with re-irradiation, and the majority of
reported symptoms occurred in the BED ≥48 Gy10 group.
There was a single reported case of grade 2 pneumonitis in
the study, which is lower than previous reports of nearly 7–
55%with the use of higher dose SBRTor EBRT re-irradiation
and much lower than Kelly et al. report of 50% grades 2 and 3
pneumonitis [7, 8, 14]. With real-time tracking and correction,
we utilized PTV margins of 5 mm around GTV compared to
the Kelly et al. method of utilizing an internal gross tumor
volume (iGTV) with 11 mm margin around the iGTV. Larger
margins around the GTV, higher dose delivered, and larger
volumes of previously non-irradiated lung tissue may have
contributed to their higher pneumonitis rates [14, 26].
In this study, progression of disease was the main cause of
morbidity after SBRT re-irradiation. Despite treatment, actuar-
ial 2-year progression-free survival of 37 % warrants new
treatment approaches and enrollment in clinical trials. The only
reported independent predictor for increased progression-free
survival with re-irradiation has been the presence of isolated
out-of-field recurrence suggestive of a metachronous lung pri-
mary [14]. Therefore, careful consideration of site and time to
recurrence is important when deciding on the appropriate dose
for re-irradiation. Despite improved outcome for re-irradiation
of out-of-field recurrences, there is potential increased toxicity
due to compromise of non-irradiated lung tissue. Dose escala-
tion for SBRT re-irradiation may improve outcome for out of
field metachronous primaries; however, this course should be
undertaken cautiously. The inclusion of potential systemic
targeted therapies and appropriate SBRT re-irradiation doses
should be considered to benefit disease-free survival and quality
of life for future treatment of in-field lung cancer recurrences
due to the significant intrathoracic and distant failure rates.
Conclusion
SBRT can be considered an option for patients with lung
cancer recurrence after high dose definitive radiation with
concurrent systemic therapy. Dose of SBRT re-irradiation
should be individualized after review of the patient’s potential
risk for toxicity and the possibility of curative approach to
optimize the quality of life for these poor prognostic patients.
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